KPV

KPV Molecular Structure & Chemical Properties

KPV peptide represents one of the most compact yet biologically active peptides under investigation for inflammatory conditions, with research spanning over three decades examining its effects in gastrointestinal, dermatological, and immune system models. Derived as the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), KPV retains the potent anti-inflammatory activity of its parent molecule while eliminating melanotropic effects such as skin pigmentation. This selective retention of therapeutic properties without broader hormonal impacts has sustained scientific interest in the peptide since its initial characterization in the late 1980s. Unlike most tripeptides that exhibit limited biological activity, KPV demonstrates remarkable stability in physiological conditions and can be administered through multiple routes including oral, subcutaneous, and topical delivery.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure consists of three amino acids in sequence, with the lysine residue providing a positive charge at physiological pH and the proline residue contributing to conformational rigidity. This simple yet specific arrangement enables cellular uptake through peptide transporters while maintaining biological activity.

KPV Mechanism of Action

KPV peptide exerts its biological effects through multiple interconnected pathways rather than a single receptor-mediated mechanism. Research demonstrates that the peptide functions primarily through intracellular anti-inflammatory signaling modulation, with cellular uptake mediated by peptide transporters. This mechanism distinguishes KPV from many peptide hormones that act exclusively through surface receptor binding.

Primary Cellular Pathways

NF-kappa-B Pathway Inhibition – Core Anti-Inflammatory Mechanism

Research has demonstrated that KPV potently inhibits activation of nuclear factor kappa-B (NF-kappa-B), a master regulator of inflammatory gene expression[1]. Key findings include:

• Nanomolar concentrations (as low as 10 nM) effectively suppress NF-kappa-B activation in intestinal epithelial cells
• Dose-dependent inhibition of I-kappa-B-alpha degradation, preventing NF-kappa-B nuclear translocation
• Reduced expression of downstream pro-inflammatory cytokines including interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1-beta (IL-1-beta)
• Effects observed across multiple cell types including immune cells and epithelial cells

Studies using NF-kappa-B luciferase reporter assays revealed up to 70% reduction in inflammatory signaling at physiological peptide concentrations[2].

PepT1 Transporter-Mediated Cellular Entry

Investigations revealed that KPV enters cells via the hydrogen ion-coupled oligopeptide transporter PepT1 (also known as SLC15A1)[1]. This transport mechanism provides:

• High-affinity cellular uptake with Km values approximately 160 micromolar in intestinal epithelial cells
• Selective targeting to inflamed tissues where PepT1 expression is upregulated
• Minimal effects in normal tissues with low PepT1 expression
• Enhanced bioavailability in inflammatory conditions

This transporter-mediated mechanism explains KPV’s selective activity in inflamed versus healthy tissues, a characteristic advantageous for therapeutic applications.

MAPK Pathway Modulation

Research indicates KPV suppresses mitogen-activated protein kinase (MAPK) inflammatory signaling cascades[1], including:

• Inhibition of ERK1/2 phosphorylation
• Reduced p38 MAPK activation
• Downstream suppression of inflammatory mediator production
• Coordinated effects with NF-kappa-B inhibition for comprehensive inflammatory control

Melanocortin Receptor System Interactions

While KPV lacks the amino acid sequence required for high-affinity binding to melanocortin receptors, research suggests potential interactions with melanocortin receptor 3 (MC3R) in specific tissues[3]:

• MC3R expression documented in airway epithelium and certain immune cells
• Potential indirect modulation of melanocortin signaling pathways
• Anti-inflammatory effects retained in MC1R-deficient mice, indicating non-MC1R mechanisms predominate
• Evidence suggests KPV’s primary mechanism differs from parent molecule alpha-MSH

Barrier Integrity Protection

Studies in intestinal models demonstrated that KPV supports epithelial barrier function[4]:

• Enhanced tight junction protein expression
• Reduced intestinal permeability in inflammatory conditions
• Protection against barrier disruption from inflammatory mediators
• Maintenance of mucosal integrity during active inflammation

KPV Research Applications & Key Findings

Inflammatory Bowel Disease Research

Colitis Models

Extensive research in murine colitis models has examined KPV’s effects on intestinal inflammation, demonstrating substantial therapeutic potential[1]. Key findings include:

• Significant reduction in dextran sulfate sodium (DSS)-induced colitis severity in mice receiving oral KPV (100 micromolar in drinking water)
• Decreased colonic infiltration of inflammatory cells by 60-70% compared to controls
• Maintenance of normal colon length during inflammatory challenge
• Reduced myeloperoxidase (MPO) activity indicating decreased neutrophil infiltration
• Marked decrease in pro-inflammatory cytokine expression (IL-1-beta, IL-6, TNF-alpha, IFN-gamma)

In TNBS (2,4,6-trinitrobenzene sulfonic acid)-induced colitis models, oral KPV administration similarly reduced inflammation and prevented body weight loss associated with severe colitis[1].

Nanoparticle Delivery Systems

Advanced delivery research demonstrated enhanced efficacy using hyaluronic acid-functionalized nanoparticles[4]:

• Targeted delivery to CD44-expressing colonic epithelial cells and macrophages
• Combined effects of accelerated mucosal healing and inflammation alleviation
• Superior therapeutic efficacy compared to conventional KPV formulations
• Colon tissue morphology in treated animals resembled healthy controls

Wound Healing and Dermatological Research

Cutaneous Wound Healing

Research examining KPV’s effects on skin repair processes revealed multiple beneficial mechanisms[5]:

• Enhanced wound closure rates in experimental models
• Reduced hypertrophic scar formation (keloid development)
• Improved collagen organization during tissue remodeling
• Anti-inflammatory effects that accelerate transition from inflammatory to proliferative healing phases

Studies demonstrated that KPV modulates NF-kappa-B signaling in wound sites, facilitating faster progression through healing stages while minimizing excessive inflammation that contributes to scarring[6].

Antimicrobial Activity

Investigations revealed dual anti-inflammatory and antimicrobial properties[5]:

• Significant inhibition of Staphylococcus aureus colony formation at picomolar to micromolar concentrations
• Bactericidal activity against both methicillin-sensitive and methicillin-resistant S. aureus strains
• Rapid killing kinetics with approximately 90% bacterial death within 15 minutes
• Antifungal effects against Candida albicans
• Antimicrobial activity comparable to parent molecule alpha-MSH

Skin Inflammatory Conditions

Research in inflammatory dermatological models suggested potential applications for:

• Psoriasis (reduction in inflammatory markers and symptom severity)
• Atopic dermatitis (decreased inflammation and improved barrier function)
• Contact dermatitis (suppression of inflammatory responses)

Respiratory System Research

Airway Inflammation

Studies in human bronchial epithelial cells demonstrated KPV’s ability to suppress respiratory inflammation[3]:

• Dose-dependent inhibition of TNF-alpha and respiratory syncytial virus (RSV)-induced NF-kappa-B activation
• Reduced IL-8 and other chemokine secretion from airway epithelial cells
• Suppression of both cellular and systemic inflammatory cues
• MC3R-mediated mechanisms in airway tissue

Research indicated potential relevance for inflammatory lung diseases including asthma and chronic obstructive pulmonary disease.

Central Nervous System Research

Traumatic Brain Injury

Investigations in traumatic brain injury (TBI) models revealed neuroprotective effects[7]:

• Reduced lesion volumes in cortical injury models following systemic KPV administration
• Improved functional outcomes in neurobehavioral testing
• Decreased inflammation and apoptosis in brain tissue
• Single-dose administration demonstrating sustained protective effects

Studies suggested KPV crosses the blood-brain barrier and exerts direct anti-inflammatory effects in neural tissue.

KPV Pharmacokinetics & Metabolism

Absorption & Distribution

KPV exhibits unusual pharmacokinetic characteristics for a tripeptide, with research demonstrating activity via multiple administration routes[1][6]. Following administration in experimental models:

• Oral bioavailability confirmed through PepT1-mediated intestinal absorption
• Stability in gastric acid allowing oral delivery without degradation
• Subcutaneous and intravenous administration achieving systemic distribution
• Transdermal delivery enhanced through iontophoresis and microneedle technologies
• Topical application demonstrating local tissue penetration

Studies using fluorescently-labeled KPV demonstrated concentration in inflamed tissues, suggesting preferential accumulation at sites of PepT1 upregulation during inflammatory states[4].

Metabolism & Elimination

The metabolic fate of KPV remains incompletely characterized, with limited pharmacokinetic data available:

• Plasma half-life expected to be short (minutes to hours) based on tripeptide characteristics
• Likely enzymatic degradation by peptidases in plasma and tissues
• Rapid clearance anticipated based on low molecular weight and hydrophilicity
• Active metabolites versus parent peptide contribution to effects unknown

A notable characteristic: despite presumed rapid plasma clearance, biological effects persist for hours following administration, suggesting either tissue retention, sustained signaling cascade activation, or effects of metabolites.

Excretion Pathways

Limited data on excretion mechanisms indicate:

• Probable renal elimination following peptidase degradation
• No accumulation detected in repeated dosing studies in animal models
• Complete characterization of excretion kinetics requires further investigation

The disconnect between expected short systemic half-life and prolonged biological activity represents an important area requiring mechanistic clarification through detailed pharmacokinetic studies.

KPV Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse KPV doses depending on species, model, and delivery route:

• Mouse colitis studies: 100 micromolar in drinking water (oral administration)
• Cell culture experiments: 10-100 nanomolar concentrations for in vitro studies
• Traumatic brain injury models: 10 micrograms total dose (intraperitoneal injection in mice)
• Topical applications: 0.1-1% cream or gel formulations in skin studies
• Transdermal delivery: Iontophoresis protocols with varied current densities

Important: These are experimental doses used in cellular and animal studies and cannot be extrapolated to other species due to significant differences in metabolism, peptide transporter expression, pharmacokinetics, and enzymatic degradation rates. Dose-response relationships vary substantially across species, making human dose predictions from animal data unreliable without clinical trials.

Administration Routes in Research

Multiple delivery methods have been investigated:

• Oral administration – Utilized in gastrointestinal research; stable in gastric environment and absorbed via intestinal PepT1
• Subcutaneous injection – Applied in systemic inflammation and neurological research models
• Intraperitoneal injection – Most common route in rodent studies for systemic delivery
• Topical application – Used in dermatological studies; enhanced by iontophoresis or microneedling
• Intravenous injection – Employed primarily in pharmacokinetic characterization studies

Common Model Organisms

KPV has been studied across multiple experimental systems:

• Mice – Primary research model (C57BL/6, BALB/c strains); majority of published in vivo data
• Rats – Used in specific traumatic brain injury and wound healing studies
• Cell culture systems – Human intestinal epithelial cells (Caco-2, HT29), human T cells (Jurkat), human bronchial epithelial cells (16HBE14o-), various primary cell cultures

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over 30 years of preclinical investigation, KPV faces substantial translational barriers that limit research applications and prevent clinical use.

Lack of Human Clinical Data

The most significant limitation is the complete absence of published human clinical trials:

• No peer-reviewed human clinical trials exist in scientific literature
• No Phase I, II, or III studies published or registered in clinical trial databases
• Human safety profile completely unestablished
• Optimal human dosing entirely unknown
• Long-term effects in humans unstudied
• Drug-drug interaction potential uncharacterized

Mechanistic Understanding Gaps

Fundamental aspects of KPV’s mechanism remain unclear:

• Relative contributions of different pathways (PepT1-mediated versus MC3R-mediated effects) incompletely understood
• Tissue-specific mechanisms require clarification
• Structure-activity relationships not fully elucidated
• Active versus inactive metabolite contributions unknown
• Optimal chemical modifications for enhanced stability unexplored in depth

Long-Term Safety Considerations

Critical safety questions remain unanswered:

• Chronic administration effects beyond several weeks unstudied even in animals
• Potential for tolerance or tachyphylaxis unknown
• Effects on cancer cell growth or tumor progression uninvestigated
• Reproductive and developmental toxicity inadequately studied
• Immunosuppression risk at higher doses uncharacterized

Regulatory & Competitive Sport Status

FDA Position

KPV has not received FDA approval for any indication:

• Classified as an unapproved drug substance
• Not recognized as Generally Recognized as Safe (GRAS)
• Not approved for human or veterinary use
• Not legally available for medical compounding in the United States under current regulations
• Listed as Category 2 substance by FDA with noted safety concerns due to insufficient clinical data

The FDA has indicated that KPV lacks adequate safety studies for approval and has classified it among substances posing potential significant safety risks when used in compounded products.

WADA Prohibition

World Anti-Doping Agency classification status:

• KPV has not been specifically named on WADA prohibited substance lists
• As an unapproved drug substance, use in competitive sports would be subject to general anti-doping regulations
• Athletes should consult current WADA guidelines and relevant sport governing bodies

Research Classification: KPV is available only for laboratory research use under appropriate institutional oversight. It is not intended for human consumption, medical use, diagnostic purposes, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H.T., Yan, Y., Sitaraman, S., & Merlin, D. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166-178. PubMed
   
2. Kannengiesser, K., Maaser, C., Heidemann, J., Luegering, A., Ross, M., Brzoska, T., Bohm, M., Luger, T.A., Domschke, W., & Kucharzik, T. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 14(3), 324-331. PubMed
   
3. Land, S.C. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: Mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology, 4(2), 59-73. PubMed
   
4. Xiao, B., Laroui, H., Viennois, E., Ayyadurai, S., Charania, M.A., Zhang, Y., Zhang, Z., Baker, M.T., Zhang, B., Gewirtz, A.T., & Merlin, D. (2017). Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy, 25(7), 1628-1640. PubMed
   
5. Bohm, M., & Luger, T.A. (2019). Are melanocortin peptides future therapeutics for cutaneous wound healing? Experimental Dermatology, 28(3), 219-225. PubMed
   
6. Pawar, K., Kolli, C.S., Rangari, V.K., & Babu, R.J. (2017). Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. Journal of Pharmaceutical Sciences, 106(7), 1814-1820. PubMed
   
7. Schaible, E.V., Steinsträßer, A., Jahn-Eimermacher, A., Luh, C., Sebastiani, A., Kornes, F., Pieter, D., Schäfer, M.K., Engelhard, K., & Thal, S.C. (2013). Single administration of tripeptide alpha-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS One, 8(8), e71056. PubMed
   
8. Hiltz, M.E., & Lipton, J.M. (1989). Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal, 3(11), 2282-2284. PubMed
   
9. Brzoska, T., Luger, T.A., Maaser, C., Abels, C., & Bohm, M. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 29(5), 581-602. PubMed
   
10. Luger, T.A., & Brzoska, T. (2007). Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases, 66(Suppl 3), iii52-iii55. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. KPV is intended for laboratory research use only.